Migraine Pain Management

Current Pharmacological and Non-pharmacological Options

Häftad, Engelska, 2024

Av Stephen B. Shrewsbury, Stephen B Shrewsbury

2 589 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.

Offers a comprehensive overview of pharmacological and alternative migraine pain treatment options
Covers the historical developments and current targets for drug development and delivery routes
Provides insights into comorbidities and their impact in patient compliance to treatment

Produktinformation

Utgivningsdatum2024-10-30
Mått216 x 276 x 31 mm
Vikt1 700 g
FormatHäftad
SpråkEngelska
Antal sidor636
FörlagElsevier Science
ISBN9780443247057

Tillhör följande kategorier

Smärta och smärtbehandling inom Medicin
Farmakologi inom Medicin
Tillverkningsindustri inom Ekonomi och ledarskap

Dr. Stephen Shrewsbury recently left Impel Pharmaceuticals where he served as Chief Medical Officer (CMO) from March 2017 and led the development of Precision Olfactory Delivery of DHE through its clinical program and to FDA approval in September 2021. Formerly Stephen was CMO at MAP Pharmaceuticals where he conducted a successful clinical program for an inhaled version of DHE, but it never got approved due to manufacturing issues. Before MAP he was at Chiron Corporation where he was also on the International Pharmaceutical Aerosol Consortium Board of Science. Before Chiron, Stephen spent 9 years with GlaxoSmithKline (last 2 in the US) having moved into the industry in 1993 after 13 years working in the UK’s National Health Service. He has also been CMO for several other West Coast (US) biotech companies; has numerous patents; written and published a book, over 40 scientific papers and nearly 200 abstracts

Part I: Foundations and historical development of migraine pain management1. Introduction2. Neuroanatomy and Neurophysiology3. Historical overview of migraine product development4. Comorbidities and their impact on therapies5. Not all Migraine attacks are the same6. Challenges and Controversies; Pharmacokinetics, Linguistics, Semantics and StatisticsPart II: Druggable targets7. CGRP8. PACAP9. Src family kinases (SFK) in Migraine10. Delta opioid receptor system11. Piezo channels in peripheral trigeminal nociception12. TRP antagonistsPart III: Drugs – Acute Management13. Simple analgesics and combination oral products14. Cannabinoids & Phytochemicals15. Ergots16. Triptans17. Beta blocker (timolol) eye drops18. Lasmiditan (and the ditan class)19. GepantsPart IV: Drugs – Prevention20. TCAs (Tricyclic Antidepresants), SNRIs, Beta blockers, candesartan, flunarizine21. Antiseizure orals (gabapentin, topiramate)22. Onabotulinumtoxin23. Gepants (for prevention)24. (CGRP) Monocloncal antibodiesPart V: Administration routes25. Oral Drugs (including SMEDDS)26. Inhaled - oral & nasal27. Subcutaneous/IM/Transcutaneous ("Injectables")28. IV/InfusionPart VI: Alternative Management29. The role of digital platforms and smartphone apps30. Herbal Medicines31. Phototherapy32. Neuromodulation33. Acupuncture (for episodic and chronic migraine)34. Manual Therapies35. Nutraceuticals and Diets36. MindfulnessPart VII: Summary & conclusion [Shrewsbury]37. Final Perspectives: oral/non-oral pharmaceuticals; devices; Complimentary practices

"...offers a thorough overview of the history, pathophysiology, and available treatments for migraine, including both pharmacological and non-pharmacological approaches.... [It] aims to give a thorough understanding of migraine as a disease and the latest advancements in the field of headache medicine,... offers a well-considered framework for those looking to build their foundational understanding of migraine pathophysiology and management,... [and] provides an extensive overview of migraine as a disease.... The writing is well organized, easy to understand, and structured with a logical flow.... written by authoritative figures in the field of headache medicine and contains a comprehensive review of migraine treatment options, book's organization and clarity make it an invaluable resource.... It is an excellent supplement to existing literature and serves as a strong reference for healthcare providers seeking to enhance their understanding of treatment strategies.... recommend[ed] for trainees and practicing clinicians looking to expand their fundamental knowledge on migraine." ©Doody's Review Service, 2025, Suraj Malhan, DO, MS (Thomas Jefferson University)